Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

Recruiting now · Phase 1/Phase 2

Conditions studied: Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma

In brief

This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the phase 2 portion, to further assess the effectiveness and safety in pediatric and young adult participants with recurrent/refractory Ewing sarcoma.

Key facts

Study ID
NCT05734066
Run by
Jazz Pharmaceuticals
People needed
60
Starts
2023-05-23
Expected to finish
2028-04-20
Last updated by the study team
2026-02-03

Who can join

Age: 2 and older, up to 30. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.